ARCHIVES

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

DCPC Board Okays Start of Low Fat High Risk Breast Cancer Study, Delays Stage 2 Trial

February 1, 1985

Treatment research Reports Summarized; New MTX Rescues

May 6, 1977

ABMT Trials Unlikely To show Clean Benefit for Breast Cancer; Data Release Debated

March 12, 1999

In Brief: David Nathan receives Lifetime Impact Award from Boston Children’s Hospital

November 7, 2014

UICC Merit Award Winners Announced

September 19, 1986

Nexavar Improves PFS In Phase III Trial

January 25, 2013